Device Firms Need More Help Making Direct-To-Consumer “Brief Statements”
This article was originally published in The Gray Sheet
Executive Summary
Device manufacturers should be given the opportunity to have FDA review their direct-to-consumer ads for restricted devices before they go public, according to AdvaMed